ID   AURKA_HUMAN             Reviewed;         403 AA.
AC   O14965; E1P5F9; O60445; O75873; Q9BQD6; Q9UPG5;
DT   27-JAN-2003, integrated into UniProtKB/Swiss-Prot.
DT   23-FEB-2022, sequence version 3.
DT   12-OCT-2022, entry version 238.
DE   RecName: Full=Aurora kinase A {ECO:0000312|HGNC:HGNC:11393};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735};
DE   AltName: Full=Aurora 2 {ECO:0000303|PubMed:10851084};
DE   AltName: Full=Aurora/IPL1-related kinase 1 {ECO:0000303|PubMed:9153231};
DE            Short=ARK-1 {ECO:0000303|PubMed:9153231};
DE            Short=Aurora-related kinase 1 {ECO:0000303|PubMed:9514916};
DE   AltName: Full=Breast tumor-amplified kinase {ECO:0000303|PubMed:11790771};
DE   AltName: Full=Ipl1- and aurora-related kinase 1 {ECO:0000250|UniProtKB:P97477};
DE   AltName: Full=Serine/threonine-protein kinase 15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022};
DE   AltName: Full=Serine/threonine-protein kinase 6 {ECO:0000303|PubMed:9771714};
DE   AltName: Full=Serine/threonine-protein kinase Ayk1 {ECO:0000250|UniProtKB:P97477};
DE   AltName: Full=Serine/threonine-protein kinase aurora-A {ECO:0000250|UniProtKB:P59241};
GN   Name=AURKA {ECO:0000312|HGNC:HGNC:11393};
GN   Synonyms=AIK {ECO:0000303|PubMed:9153231}, AIRK1
GN   {ECO:0000312|HGNC:HGNC:11393}, ARK1 {ECO:0000312|HGNC:HGNC:11393},
GN   AURA {ECO:0000312|HGNC:HGNC:11393}, AYK1
GN   {ECO:0000250|UniProtKB:P97477}, BTAK {ECO:0000303|PubMed:9771714},
GN   IAK1 {ECO:0000250|UniProtKB:P97477}, STK15
GN   {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}, STK6
GN   {ECO:0000303|PubMed:9771714};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, SUBCELLULAR LOCATION, AND VARIANT
RP   VAL-57.
RC   TISSUE=Blood;
RX   PubMed=9153231; DOI=10.1074/jbc.272.21.13766;
RA   Kimura M., Kotani S., Hattori T., Sumi N., Yoshioka T., Todokoro K.,
RA   Okano Y.;
RT   "Cell cycle-dependent expression and spindle pole localization of a novel
RT   human protein kinase, Aik, related to Aurora of Drosophila and yeast
RT   Ipl1.";
RL   J. Biol. Chem. 272:13766-13771(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-57.
RX   PubMed=9514916; DOI=10.1006/bbrc.1998.8250;
RA   Shindo M., Nakano H., Kuroyanagi H., Shirasawa T., Mihara M., Gilbert D.J.,
RA   Jenkins N.A., Copeland N.G., Yagita H., Okumura K.;
RT   "cDNA cloning, expression, subcellular localization, and chromosomal
RT   assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1
RT   and 2.";
RL   Biochem. Biophys. Res. Commun. 244:285-292(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-31 AND VAL-57.
RC   TISSUE=Mammary gland;
RX   PubMed=9771714; DOI=10.1038/2496;
RA   Zhou H., Kuang J., Zhong L., Kuo W.-L., Gray J.W., Sahin A., Brinkley B.R.,
RA   Sen S.;
RT   "Tumour amplified kinase STK15/BTAK induces centrosome amplification,
RT   aneuploidy and transformation.";
RL   Nat. Genet. 20:189-193(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Wang L., Thibodeau S.N.;
RT   "Mutational analysis of the STK15 gene in human tumors.";
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-57.
RC   TISSUE=Cervix, Colon, Kidney, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=9606188; DOI=10.1093/emboj/17.11.3052;
RA   Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B.,
RA   Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S.,
RA   Novotny M., Slamon D.J., Plowman G.D.;
RT   "A homologue of Drosophila aurora kinase is oncogenic and amplified in
RT   human colorectal cancers.";
RL   EMBO J. 17:3052-3065(1998).
RN   [9]
RP   UBIQUITINATION, PROTEASOMAL DEGRADATION, AND MUTAGENESIS OF ARG-205.
RX   PubMed=10851084; DOI=10.1038/sj.onc.1203609;
RA   Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H.,
RA   Furukawa K., Urano T.;
RT   "Degradation of human Aurora2 protein kinase by the anaphase-promoting
RT   complex-ubiquitin-proteasome pathway.";
RL   Oncogene 19:2812-2819(2000).
RN   [10]
RP   FUNCTION, PHOSPHORYLATION AT THR-288, MUTAGENESIS OF THR-288,
RP   UBIQUITINATION, AND ACTIVITY REGULATION.
RX   PubMed=11039908; DOI=10.1038/sj.onc.1203847;
RA   Walter A.O., Seghezzi W., Korver W., Sheung J., Lees E.;
RT   "The mitotic serine/threonine kinase Aurora2/AIK is regulated by
RT   phosphorylation and degradation.";
RL   Oncogene 19:4906-4916(2000).
RN   [11]
RP   FUNCTION, INTERACTION WITH PPP1CA; PPP1CB AND PPP1CC, MUTAGENESIS OF
RP   PHE-165 AND PHE-346, AND PHOSPHORYLATION.
RX   PubMed=11551964; DOI=10.1074/jbc.m107540200;
RA   Katayama H., Zhou H., Li Q., Tatsuka M., Sen S.;
RT   "Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and
RT   protein phosphatase 1 through mitotic cell division cycle.";
RL   J. Biol. Chem. 276:46219-46224(2001).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12576638; DOI=10.1247/csf.27.457;
RA   Sugimoto K., Urano T., Zushi H., Inoue K., Tasaka H., Tachibana M.,
RA   Dotsu M.;
RT   "Molecular dynamics of Aurora-A kinase in living mitotic cells
RT   simultaneously visualized with histone H3 and nuclear membrane protein
RT   importinalpha.";
RL   Cell Struct. Funct. 27:457-467(2002).
RN   [13]
RP   FUNCTION, INDUCTION, PHOSPHORYLATION, AND ACTIVITY REGULATION.
RX   PubMed=12390251; DOI=10.1046/j.1365-2443.2002.00592.x;
RA   Marumoto T., Hirota T., Morisaki T., Kunitoku N., Zhang D., Ichikawa Y.,
RA   Sasayama T., Kuninaka S., Mimori T., Tamaki N., Kimura M., Okano Y.,
RA   Saya H.;
RT   "Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian
RT   cells.";
RL   Genes Cells 7:1173-1182(2002).
RN   [14]
RP   INDUCTION.
RX   PubMed=11790771; DOI=10.1074/jbc.m108252200;
RA   Tanaka M., Ueda A., Kanamori H., Ideguchi H., Yang J., Kitajima S.,
RA   Ishigatsubo Y.;
RT   "Cell-cycle-dependent regulation of human aurora A transcription is
RT   mediated by periodic repression of E4TF1.";
RL   J. Biol. Chem. 277:10719-10726(2002).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-288.
RX   PubMed=13678582; DOI=10.1016/s0092-8674(03)00642-1;
RA   Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M.,
RA   Hatakeyama K., Saya H.;
RT   "Aurora-A and an interacting activator, the LIM protein Ajuba, are required
RT   for mitotic commitment in human cells.";
RL   Cell 114:585-598(2003).
RN   [16]
RP   FUNCTION.
RX   PubMed=14523000; DOI=10.1074/jbc.m306275200;
RA   Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E., Saya H.;
RT   "Aurora-A kinase maintains the fidelity of early and late mitotic events in
RT   HeLa cells.";
RL   J. Biol. Chem. 278:51786-51795(2003).
RN   [17]
RP   INTERACTION WITH TACC1.
RX   PubMed=14603251; DOI=10.1038/sj.onc.1206972;
RA   Conte N., Delaval B., Ginestier C., Ferrand A., Isnardon D., Larroque C.,
RA   Prigent C., Seraphin B., Jacquemier J., Birnbaum D.;
RT   "TACC1-chTOG-Aurora A protein complex in breast cancer.";
RL   Oncogene 22:8102-8116(2003).
RN   [18]
RP   FUNCTION.
RX   PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x;
RA   Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S.,
RA   Tamai K., Nojima H.;
RT   "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A
RT   kinase.";
RL   Genes Cells 9:383-397(2004).
RN   [19]
RP   RETRACTED PAPER.
RX   PubMed=14990569; DOI=10.1074/jbc.m311780200;
RA   Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A.,
RA   Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.;
RT   "BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M
RT   transition.";
RL   J. Biol. Chem. 279:19643-19648(2004).
RN   [20]
RP   RETRACTION NOTICE OF PUBMED:14990569.
RX   PubMed=26341884; DOI=10.1074/jbc.a115.311780;
RA   Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A.,
RA   Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.;
RL   J. Biol. Chem. 290:22311-22311(2015).
RN   [21]
RP   FUNCTION.
RX   PubMed=15128871; DOI=10.1242/jcs.01108;
RA   Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V., Dozier C.,
RA   Mirey G., Bouche J.P., Theis-Febvre N., Schmitt E., Monsarrat B.,
RA   Prigent C., Ducommun B.;
RT   "Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the
RT   G2-M transition.";
RL   J. Cell Sci. 117:2523-2531(2004).
RN   [22]
RP   FUNCTION, MUTAGENESIS OF LYS-162, AND INTERACTION WITH TP53.
RX   PubMed=14702041; DOI=10.1038/ng1279;
RA   Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F.,
RA   Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.;
RT   "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization
RT   and inhibition of p53.";
RL   Nat. Genet. 36:55-62(2004).
RN   [23]
RP   INTERACTION WITH CPEB1.
RX   PubMed=15966895; DOI=10.1111/j.1365-2443.2005.00870.x;
RA   Sasayama T., Marumoto T., Kunitoku N., Zhang D., Tamaki N., Kohmura E.,
RA   Saya H., Hirota T.;
RT   "Over-expression of Aurora-A targets cytoplasmic polyadenylation element
RT   binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1.";
RL   Genes Cells 10:627-638(2005).
RN   [24]
RP   PHOSPHORYLATION AT THR-288 AND SER-342.
RX   PubMed=16246726; DOI=10.1016/j.molcel.2005.08.035;
RA   Zhao Z.S., Lim J.P., Ng Y.W., Lim L., Manser E.;
RT   "The GIT-associated kinase PAK targets to the centrosome and regulates
RT   Aurora-A.";
RL   Mol. Cell 20:237-249(2005).
RN   [25]
RP   INDUCTION, AND FUNCTION.
RX   PubMed=15987997; DOI=10.1128/mcb.25.14.5789-5800.2005;
RA   Yu C.T., Hsu J.M., Lee Y.C., Tsou A.P., Chou C.K., Huang C.Y.;
RT   "Phosphorylation and stabilization of HURP by Aurora-A: implication of HURP
RT   as a transforming target of Aurora-A.";
RL   Mol. Cell. Biol. 25:5789-5800(2005).
RN   [26]
RP   INTERACTION WITH BORA.
RX   PubMed=16890155; DOI=10.1016/j.devcel.2006.06.002;
RA   Hutterer A., Berdnik D., Wirtz-Peitz F., Zigman M., Schleiffer A.,
RA   Knoblich J.A.;
RT   "Mitotic activation of the kinase Aurora-A requires its binding partner
RT   Bora.";
RL   Dev. Cell 11:147-157(2006).
RN   [27]
RP   FUNCTION.
RX   PubMed=18056443; DOI=10.1158/0008-5472.can-07-2578;
RA   Sankaran S., Crone D.E., Palazzo R.E., Parvin J.D.;
RT   "Aurora-A kinase regulates breast cancer associated gene 1 inhibition of
RT   centrosome-dependent microtubule nucleation.";
RL   Cancer Res. 67:11186-11194(2007).
RN   [28]
RP   FUNCTION, INTERACTION WITH HDAC6, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ASP-274 AND THR-288.
RX   PubMed=17604723; DOI=10.1016/j.cell.2007.04.035;
RA   Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., Golemis E.A.;
RT   "HEF1-dependent Aurora A activation induces disassembly of the primary
RT   cilium.";
RL   Cell 129:1351-1363(2007).
RN   [29]
RP   INTERACTION WITH ARHGEF2.
RX   PubMed=17488622; DOI=10.1016/j.devcel.2007.03.014;
RA   Birkenfeld J., Nalbant P., Bohl B.P., Pertz O., Hahn K.M., Bokoch G.M.;
RT   "GEF-H1 modulates localized RhoA activation during cytokinesis under the
RT   control of mitotic kinases.";
RL   Dev. Cell 12:699-712(2007).
RN   [30]
RP   SUBCELLULAR LOCATION, INTERACTION WITH PPP2CA, AND PHOSPHORYLATION AT
RP   SER-51.
RX   PubMed=17229885; DOI=10.1091/mbc.e06-12-1152;
RA   Horn V., Thelu J., Garcia A., Albiges-Rizo C., Block M.R., Viallet J.;
RT   "Functional interaction of Aurora-A and PP2A during mitosis.";
RL   Mol. Biol. Cell 18:1233-1241(2007).
RN   [31]
RP   INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION.
RX   PubMed=17726514; DOI=10.1371/journal.pone.0000784;
RA   North B.J., Verdin E.;
RT   "Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during
RT   mitosis.";
RL   PLoS ONE 2:E784-E784(2007).
RN   [32]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=17360485; DOI=10.1073/pnas.0608798104;
RA   Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O.,
RA   Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., Ray E.T.,
RA   Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S.,
RA   Wysong D.R., Zhang M., Bolen J.B., Claiborne C.F.;
RT   "Antitumor activity of MLN8054, an orally active small-molecule inhibitor
RT   of Aurora A kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:4106-4111(2007).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [34]
RP   FUNCTION.
RX   PubMed=18615013; DOI=10.1038/nature07185;
RA   Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R.,
RA   Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.;
RT   "Polo-like kinase-1 is activated by aurora A to promote checkpoint
RT   recovery.";
RL   Nature 455:119-123(2008).
RN   [35]
RP   FUNCTION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PARD3.
RX   PubMed=19812038; DOI=10.1074/jbc.m109.055897;
RA   Khazaei M.R., Puschel A.W.;
RT   "Phosphorylation of the par polarity complex protein Par3 at serine 962 is
RT   mediated by aurora A and regulates its function in neuronal polarity.";
RL   J. Biol. Chem. 284:33571-33579(2009).
RN   [36]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KIF2A.
RX   PubMed=19351716; DOI=10.1242/jcs.044321;
RA   Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.;
RT   "Plk1 and Aurora A regulate the depolymerase activity and the cellular
RT   localization of Kif2a.";
RL   J. Cell Sci. 122:1334-1341(2009).
RN   [37]
RP   FUNCTION, INTERACTION WITH TPX2, PHOSPHORYLATION AT THR-287 AND THR-288,
RP   AND MUTAGENESIS OF THR-287.
RX   PubMed=19668197; DOI=10.1038/ncb1919;
RA   Mori D., Yamada M., Mimori-Kiyosue Y., Shirai Y., Suzuki A., Ohno S.,
RA   Saya H., Wynshaw-Boris A., Hirotsune S.;
RT   "An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite elongation
RT   by modulation of microtubule dynamics.";
RL   Nat. Cell Biol. 11:1057-1068(2009).
RN   [38]
RP   INTERACTION WITH TPX2, MUTAGENESIS OF GLY-198, AND SUBCELLULAR LOCATION.
RX   PubMed=19357306; DOI=10.1073/pnas.0900833106;
RA   Fu J., Bian M., Liu J., Jiang Q., Zhang C.;
RT   "A single amino acid change converts Aurora-A into Aurora-B-like kinase in
RT   terms of partner specificity and cellular function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:6939-6944(2009).
RN   [39]
RP   FUNCTION, INTERACTION WITH PIFO, AND ACTIVATION BY PIFO.
RX   PubMed=20643351; DOI=10.1016/j.devcel.2010.06.005;
RA   Kinzel D., Boldt K., Davis E.E., Burtscher I., Trumbach D., Diplas B.,
RA   Attie-Bitach T., Wurst W., Katsanis N., Ueffing M., Lickert H.;
RT   "Pitchfork regulates primary cilia disassembly and left-right asymmetry.";
RL   Dev. Cell 19:66-77(2010).
RN   [40]
RP   IDENTIFICATION IN A COMPLEX WITH AUNIP AND NIN.
RX   PubMed=20596670; DOI=10.3892/ijo_00000691;
RA   Lieu A.S., Cheng T.S., Chou C.H., Wu C.H., Hsu C.Y., Huang C.Y.,
RA   Chang L.K., Loh J.K., Chang C.S., Hsu C.M., Howng S.L., Hong Y.R.;
RT   "Functional characterization of AIBp, a novel Aurora-A binding protein in
RT   centrosome structure and spindle formation.";
RL   Int. J. Oncol. 37:429-436(2010).
RN   [41]
RP   INTERACTION WITH GADD45A.
RX   PubMed=20460379; DOI=10.1074/jbc.m109.069344;
RA   Sanchez R., Pantoja-Uceda D., Prieto J., Diercks T., Marcaida M.J.,
RA   Montoya G., Campos-Olivas R., Blanco F.J.;
RT   "Solution structure of human growth arrest and DNA damage 45alpha
RT   (Gadd45alpha) and its interactions with proliferating cell nuclear antigen
RT   (PCNA) and Aurora A kinase.";
RL   J. Biol. Chem. 285:22196-22201(2010).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [43]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH JTB.
RX   PubMed=21225229; DOI=10.3892/ijo.2011.900;
RA   Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.;
RT   "PAR, a protein involved in the cell cycle, is functionally related to
RT   chromosomal passenger proteins.";
RL   Int. J. Oncol. 38:777-785(2011).
RN   [44]
RP   REVIEW ON FUNCTION.
RX   PubMed=14625535; DOI=10.1038/nrm1245;
RA   Carmena M., Earnshaw W.C.;
RT   "The cellular geography of aurora kinases.";
RL   Nat. Rev. Mol. Cell Biol. 4:842-854(2003).
RN   [45]
RP   REVIEW ON FUNCTION.
RX   PubMed=19774610; DOI=10.1002/em.20533;
RA   Lukasiewicz K.B., Lingle W.L.;
RT   "Aurora A, centrosome structure, and the centrosome cycle.";
RL   Environ. Mol. Mutagen. 50:602-619(2009).
RN   [46]
RP   INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION.
RX   PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004;
RA   Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X., Li C.,
RA   Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H., Cha Y.I.,
RA   Gius D., Deng C.X.;
RT   "SIRT2 maintains genome integrity and suppresses tumorigenesis through
RT   regulating APC/C activity.";
RL   Cancer Cell 20:487-499(2011).
RN   [47]
RP   INTERACTION WITH HNRNPU.
RX   PubMed=21242313; DOI=10.1242/jcs.063347;
RA   Ma N., Matsunaga S., Morimoto A., Sakashita G., Urano T., Uchiyama S.,
RA   Fukui K.;
RT   "The nuclear scaffold protein SAF-A is required for kinetochore-microtubule
RT   attachment and contributes to the targeting of Aurora-A to mitotic
RT   spindles.";
RL   J. Cell Sci. 124:394-404(2011).
RN   [48]
RP   INTERACTION WITH KLHL18 AND CUL3, UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=23213400; DOI=10.1242/bio.2011018;
RA   Moghe S., Jiang F., Miura Y., Cerny R.L., Tsai M.Y., Furukawa M.;
RT   "The CUL3-KLHL18 ligase regulates mitotic entry and ubiquitylates Aurora-
RT   A.";
RL   Biol. Open 1:82-91(2012).
RN   [49]
RP   INTERACTION WITH FRY.
RX   PubMed=22753416; DOI=10.1074/jbc.m112.378968;
RA   Ikeda M., Chiba S., Ohashi K., Mizuno K.;
RT   "Furry protein promotes Aurora A-mediated polo-like kinase 1 activation.";
RL   J. Biol. Chem. 287:27670-27681(2012).
RN   [50]
RP   SUBCELLULAR LOCATION.
RX   PubMed=25657325; DOI=10.1091/mbc.e14-09-1366;
RA   Ohta S., Wood L., Toramoto I., Yagyu K., Fukagawa T., Earnshaw W.C.;
RT   "CENP-32 is required to maintain centrosomal dominance in bipolar spindle
RT   assembly.";
RL   Mol. Biol. Cell 26:1225-1237(2015).
RN   [51]
RP   INTERACTION WITH HNRNPU.
RX   PubMed=25986610; DOI=10.1128/mcb.01312-14;
RA   Douglas P., Ye R., Morrice N., Britton S., Trinkle-Mulcahy L.,
RA   Lees-Miller S.P.;
RT   "Phosphorylation of SAF-A/hnRNP-U serine 59 by polo-like kinase 1 is
RT   required for mitosis.";
RL   Mol. Cell. Biol. 35:2699-2713(2015).
RN   [52]
RP   FUNCTION.
RX   PubMed=27335426; DOI=10.1242/jcs.184416;
RA   Kotak S., Afshar K., Busso C., Goenczy P.;
RT   "Aurora A kinase regulates proper spindle positioning in C. elegans and in
RT   human cells.";
RL   J. Cell Sci. 129:3015-3025(2016).
RN   [53]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [54]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH
RP   FOXP1.
RX   PubMed=28218735; DOI=10.1038/oncsis.2016.80;
RA   Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W.,
RA   Liu Q.;
RT   "Aurora kinase A regulates Survivin stability through targeting FBXL7 in
RT   gastric cancer drug resistance and prognosis.";
RL   Oncogenesis 6:E298-E298(2017).
RN   [55]
RP   SUBCELLULAR LOCATION.
RX   PubMed=30538148; DOI=10.1261/rna.069773.118;
RA   Jiao A.L., Perales R., Umbreit N.T., Haswell J.R., Piper M.E., Adams B.D.,
RA   Pellman D., Kennedy S., Slack F.J.;
RT   "Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing
RT   factor.";
RL   RNA 25:352-363(2019).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 107-403 IN COMPLEX WITH ADENOSINE,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=12237287; DOI=10.1074/jbc.c200426200;
RA   Cheetham G.M., Knegtel R.M., Coll J.T., Renwick S.B., Swenson L., Weber P.,
RA   Lippke J.A., Austen D.A.;
RT   "Crystal structure of aurora-2, an oncogenic serine/threonine kinase.";
RL   J. Biol. Chem. 277:42419-42422(2002).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 125-391 IN COMPLEX WITH ADP.
RX   PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3;
RA   Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G.,
RA   Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V.,
RA   Thompson D.A.;
RT   "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases
RT   from nanovolume crystallography.";
RL   Structure 10:1659-1667(2002).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 122-403 IN COMPLEX WITH TPX2,
RP   MUTAGENESIS OF ASP-274, ACTIVE SITE, PHOSPHORYLATION AT THR-287 AND
RP   THR-288, AND REGION ACTIVATION SEGMENT.
RX   PubMed=14580337; DOI=10.1016/s1097-2765(03)00392-7;
RA   Bayliss R., Sardon T., Vernos I., Conti E.;
RT   "Structural basis of Aurora-A activation by TPX2 at the mitotic spindle.";
RL   Mol. Cell 12:851-862(2003).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 123-401 IN COMPLEXES WITH ADPNP
RP   AND 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=16337122; DOI=10.1016/j.bmcl.2005.11.053;
RA   Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S.,
RA   Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A.,
RA   Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., Rowsell S.;
RT   "SAR and inhibitor complex structure determination of a novel class of
RT   potent and specific Aurora kinase inhibitors.";
RL   Bioorg. Med. Chem. Lett. 16:1320-1323(2006).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 100-403 IN COMPLEXES WITH
RP   SYNTHETIC INHIBITORS, AND FUNCTION.
RX   PubMed=17125279; DOI=10.1021/jm060897w;
RA   Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D., Bindi S.,
RA   Cameron A., Candiani I., Cappella P., Carpinelli P., Croci W., Forte B.,
RA   Giorgini M.L., Klapwijk J., Marsiglio A., Pesenti E., Rocchetti M.,
RA   Roletto F., Severino D., Soncini C., Storici P., Tonani R., Zugnoni P.,
RA   Vianello P.;
RT   "1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent
RT   aurora kinase inhibitor with a favorable antitumor kinase inhibition
RT   profile.";
RL   J. Med. Chem. 49:7247-7251(2006).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 125-391 IN COMPLEX WITH VX-680 AND
RP   TPX2, PHOSPHORYLATION AT THR-288, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   SUBUNIT.
RX   PubMed=18662907; DOI=10.1110/ps.036590.108;
RA   Zhao B., Smallwood A., Yang J., Koretke K., Nurse K., Calamari A.,
RA   Kirkpatrick R.B., Lai Z.;
RT   "Modulation of kinase-inhibitor interactions by auxiliary protein binding:
RT   crystallography studies on Aurora A interactions with VX-680 and with
RT   TPX2.";
RL   Protein Sci. 17:1791-1797(2008).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 127-388 IN COMPLEX WITH ADP,
RP   CHARACTERIZATION OF VARIANTS ARG-155 AND MET-174, AND INTERACTION WITH
RP   TPX2.
RX   PubMed=19801554; DOI=10.1074/jbc.m109.032722;
RA   Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R.,
RA   Bayliss R., Linardopoulos S.;
RT   "A cancer-associated aurora A mutant is mislocalized and misregulated due
RT   to loss of interaction with TPX2.";
RL   J. Biol. Chem. 284:33177-33184(2009).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 123-401 IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19140666; DOI=10.1021/jm801270e;
RA   Coumar M.S., Leou J.S., Shukla P., Wu J.S., Dixit A.K., Lin W.H.,
RA   Chang C.Y., Lien T.W., Tan U.K., Chen C.H., Hsu J.T., Chao Y.S., Wu S.Y.,
RA   Hsieh H.P.;
RT   "Structure-based drug design of novel Aurora kinase A inhibitors:
RT   structural basis for potency and specificity.";
RL   J. Med. Chem. 52:1050-1062(2009).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 125-391 IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=19402633; DOI=10.1021/jm9000314;
RA   Aliagas-Martin I., Burdick D., Corson L., Dotson J., Drummond J.,
RA   Fields C., Huang O.W., Hunsaker T., Kleinheinz T., Krueger E., Liang J.,
RA   Moffat J., Phillips G., Pulk R., Rawson T.E., Ultsch M., Walker L.,
RA   Wiesmann C., Zhang B., Zhu B.Y., Cochran A.G.;
RT   "A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually
RT   high selectivity against Aurora B.";
RL   J. Med. Chem. 52:3300-3307(2009).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 122-403 OF MUTANTS ALA-290 AND
RP   ALA-393 IN COMPLEX WITH ADP, INTERACTION WITH MYCN AND TPX2, MUTAGENESIS OF
RP   CYS-290; TYR-334; GLN-335 AND CYS-393, AND CATALYTIC ACTIVITY.
RX   PubMed=27837025; DOI=10.1073/pnas.1610626113;
RA   Richards M.W., Burgess S.G., Poon E., Carstensen A., Eilers M., Chesler L.,
RA   Bayliss R.;
RT   "Structural basis of N-Myc binding by Aurora-A and its destabilization by
RT   kinase inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:13726-13731(2016).
RN   [66]
RP   VARIANTS ILE-31 AND VAL-57, AND CHARACTERIZATION OF VARIANT VAL-57.
RX   PubMed=15867347; DOI=10.1158/0008-5472.can-04-2149;
RA   Kimura M.T., Mori T., Conroy J., Nowak N.J., Satomi S., Tamai K.,
RA   Nagase H.;
RT   "Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A)
RT   coordinately increase esophageal cancer risk.";
RL   Cancer Res. 65:3548-3554(2005).
RN   [67]
RP   VARIANTS ILE-31 AND VAL-57.
RX   PubMed=16011022;
RA   Chen L., Ao X., Ren Q., Wang Z.N., Lu C., Xu Y., Jiang L., Luo Y., Xu H.M.,
RA   Zhang X.;
RT   "Linkage disequilibrium and haplotype analysis of two single nucleotide
RT   polymorphisms in STK15 in Chinese.";
RL   Yi Chuan Xue Bao 32:331-336(2005).
RN   [68]
RP   VARIANT ILE-31.
RX   PubMed=16762494; DOI=10.1016/j.canlet.2006.05.002;
RA   Tchatchou S., Wirtenberger M., Hemminki K., Sutter C., Meindl A.,
RA   Wappenschmidt B., Kiechle M., Bugert P., Schmutzler R.K., Bartram C.R.,
RA   Burwinkel B.;
RT   "Aurora kinases A and B and familial breast cancer risk.";
RL   Cancer Lett. 247:266-272(2007).
RN   [69]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-31; LEU-50; VAL-57; ARG-155; MET-174
RP   AND VAL-373.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [70]
RP   IDENTIFICATION IN A COMPLEX WITH NEDD9 AND CTTN.
RX   PubMed=24574519; DOI=10.1158/1541-7786.mcr-13-0654;
RA   Kozyreva V.K., McLaughlin S.L., Livengood R.H., Calkins R.A., Kelley L.C.,
RA   Rajulapati A., Ice R.J., Smolkin M.B., Weed S.A., Pugacheva E.N.;
RT   "NEDD9 regulates actin dynamics through cortactin deacetylation in an
RT   AURKA/HDAC6-dependent manner.";
RL   Mol. Cancer Res. 12:681-693(2014).
RN   [71]
RP   FUNCTION, INTERACTION WITH AAAS, SUBCELLULAR LOCATION, AND PHOSPHORYLATION
RP   AT THR-288.
RX   PubMed=26246606; DOI=10.1091/mbc.e15-02-0113;
RA   Carvalhal S., Ribeiro S.A., Arocena M., Kasciukovic T., Temme A.,
RA   Koehler K., Huebner A., Griffis E.R.;
RT   "The nucleoporin ALADIN regulates Aurora A localization to ensure robust
RT   mitotic spindle formation.";
RL   Mol. Biol. Cell 26:3424-3438(2015).
CC   -!- FUNCTION: Mitotic serine/threonine kinase that contributes to the
CC       regulation of cell cycle progression (PubMed:26246606, PubMed:12390251,
CC       PubMed:18615013, PubMed:11039908, PubMed:17125279, PubMed:17360485).
CC       Associates with the centrosome and the spindle microtubules during
CC       mitosis and plays a critical role in various mitotic events including
CC       the establishment of mitotic spindle, centrosome duplication,
CC       centrosome separation as well as maturation, chromosomal alignment,
CC       spindle assembly checkpoint, and cytokinesis (PubMed:26246606,
CC       PubMed:14523000). Required for normal spindle positioning during
CC       mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex
CC       during metaphase (PubMed:27335426). Required for initial activation of
CC       CDK1 at centrosomes (PubMed:13678582, PubMed:15128871). Phosphorylates
CC       numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B,
CC       DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3,
CC       p53/TP53 and TPX2 (PubMed:18056443, PubMed:15128871, PubMed:14702041,
CC       PubMed:11551964, PubMed:15147269, PubMed:15987997, PubMed:17604723,
CC       PubMed:18615013). Regulates KIF2A tubulin depolymerase activity
CC       (PubMed:19351716). Important for microtubule formation and/or
CC       stabilization (PubMed:18056443). Required for normal axon formation
CC       (PubMed:19812038). Plays a role in microtubule remodeling during
CC       neurite extension (PubMed:19668197). Also acts as a key regulatory
CC       component of the p53/TP53 pathway, and particularly the checkpoint-
CC       response pathways critical for oncogenic transformation of cells, by
CC       phosphorylating and destabilizing p53/TP53 (PubMed:14702041).
CC       Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1)
CC       isoforms, to inhibit their activity (PubMed:11551964). Inhibits cilia
CC       outgrowth (By similarity). Required for cilia disassembly via
CC       phosphorylation of HDAC6 and subsequent deacetylation of alpha-tubulin
CC       (PubMed:17604723, PubMed:20643351). Regulates protein levels of the
CC       anti-apoptosis protein BIRC5 by suppressing the expression of the
CC       SCF(FBXL7) E3 ubiquitin-protein ligase substrate adapter FBXL7 through
CC       the phosphorylation of the transcription factor FOXP1
CC       (PubMed:28218735). {ECO:0000250|UniProtKB:A0A8I3S724,
CC       ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964,
CC       ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582,
CC       ECO:0000269|PubMed:14523000, ECO:0000269|PubMed:14702041,
CC       ECO:0000269|PubMed:15128871, ECO:0000269|PubMed:15147269,
CC       ECO:0000269|PubMed:15987997, ECO:0000269|PubMed:17125279,
CC       ECO:0000269|PubMed:17360485, ECO:0000269|PubMed:17604723,
CC       ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:18615013,
CC       ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19668197,
CC       ECO:0000269|PubMed:19812038, ECO:0000269|PubMed:20643351,
CC       ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27335426,
CC       ECO:0000269|PubMed:28218735}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122,
CC         ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633,
CC         ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:12237287,
CC         ECO:0000269|PubMed:16337122, ECO:0000269|PubMed:19140666,
CC         ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:27837025,
CC         ECO:0000269|PubMed:28218735};
CC   -!- ACTIVITY REGULATION: Activation of CDK1, appears to be an upstream
CC       event of AURKA activation. Phosphatase inhibitor-2 (PPP1R2) and TPX2
CC       act also as activators. Inactivated by the G2 checkpoint. Inhibited by
CC       GADD45A and p53/TP53, and through dephosphorylation by protein
CC       phosphatase type 1 (PP1). MLN8054 is also a potent and selective
CC       inhibitor. Activated during the early phase of cilia disassembly in the
CC       presence of PIFO. Inhibited by the small molecule inhibitor VX-680
CC       (PubMed:28218735). {ECO:0000269|PubMed:11039908,
CC       ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:17360485,
CC       ECO:0000269|PubMed:28218735}.
CC   -!- SUBUNIT: Part of a complex composed of NEDD9, AURKA and CTTN; within
CC       the complex NEDD9 acts as a scaffold protein and is required for
CC       complex formation (PubMed:24574519). Identified in a complex with AUNIP
CC       and NIN (PubMed:20596670). Interacts with FBXL7 (By similarity).
CC       Interacts with CPEB1, JTB, TACC1, TPX2, PPP2CA, as well as with the
CC       protein phosphatase type 1 (PP1) isoforms PPP1CA, PPP1CB and PPP1CC
CC       (PubMed:15966895, PubMed:21225229, PubMed:14603251, PubMed:19668197,
CC       PubMed:19357306, PubMed:14580337, PubMed:18662907, PubMed:19801554,
CC       PubMed:27837025, PubMed:17229885, PubMed:11551964). Interacts also with
CC       its substrates ARHGEF2, BORA, KIF2A, PARD3, and p53/TP53
CC       (PubMed:17488622, PubMed:16890155, PubMed:19351716, PubMed:19812038,
CC       PubMed:14702041). Interaction with BORA promotes phosphorylation of
CC       PLK1 (By similarity). Interacts with PIFO (PubMed:20643351). Interacts
CC       with GADD45A, competing with its oligomerization (PubMed:20460379).
CC       Interacts (via C-terminus) with AUNIP (via C-terminus)
CC       (PubMed:20596670). Interacts with FRY; this interaction facilitates
CC       AURKA-mediated PLK1 phosphorylation (PubMed:22753416). Interacts with
CC       SIRT2 (PubMed:17726514, PubMed:22014574). Interacts with MYCN;
CC       interaction is phospho-independent and triggers AURKA activation; AURKA
CC       competes with FBXW7 for binding to unphosphorylated MYCN but not for
CC       binding to phosphorylated MYCN (PubMed:27837025). Interacts with HNRNPU
CC       (PubMed:21242313, PubMed:25986610). Interacts with AAAS
CC       (PubMed:26246606). Interacts with KLHL18 and CUL3 (PubMed:23213400).
CC       Interacts with FOXP1 (PubMed:28218735). Interacts with HDAC6; AURKA-
CC       mediated phosphorylation of HDAC6 promotes deacetylation of alpha-
CC       tubulin (PubMed:17604723). {ECO:0000250|UniProtKB:P97477,
CC       ECO:0000269|PubMed:11551964, ECO:0000269|PubMed:12237287,
CC       ECO:0000269|PubMed:12467573, ECO:0000269|PubMed:14580337,
CC       ECO:0000269|PubMed:14603251, ECO:0000269|PubMed:14702041,
CC       ECO:0000269|PubMed:15966895, ECO:0000269|PubMed:16890155,
CC       ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:17488622,
CC       ECO:0000269|PubMed:17604723, ECO:0000269|PubMed:17726514,
CC       ECO:0000269|PubMed:18662907, ECO:0000269|PubMed:19140666,
CC       ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19357306,
CC       ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:19668197,
CC       ECO:0000269|PubMed:19801554, ECO:0000269|PubMed:19812038,
CC       ECO:0000269|PubMed:20460379, ECO:0000269|PubMed:20596670,
CC       ECO:0000269|PubMed:20643351, ECO:0000269|PubMed:21225229,
CC       ECO:0000269|PubMed:21242313, ECO:0000269|PubMed:22014574,
CC       ECO:0000269|PubMed:22753416, ECO:0000269|PubMed:23213400,
CC       ECO:0000269|PubMed:24574519, ECO:0000269|PubMed:25986610,
CC       ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27837025,
CC       ECO:0000269|PubMed:28218735}.
CC   -!- INTERACTION:
CC       O14965; Q9NWT8: AURKAIP1; NbExp=2; IntAct=EBI-448680, EBI-448665;
CC       O14965; O15392: BIRC5; NbExp=2; IntAct=EBI-448680, EBI-518823;
CC       O14965; P00533: EGFR; NbExp=4; IntAct=EBI-448680, EBI-297353;
CC       O14965; P61978: HNRNPK; NbExp=2; IntAct=EBI-448680, EBI-304185;
CC       O14965; Q13123: IK; NbExp=3; IntAct=EBI-448680, EBI-713456;
CC       O14965; O14920: IKBKB; NbExp=2; IntAct=EBI-448680, EBI-81266;
CC       O14965; Q9NQS7: INCENP; NbExp=2; IntAct=EBI-448680, EBI-307907;
CC       O14965; Q9NQS7-1: INCENP; NbExp=2; IntAct=EBI-448680, EBI-15767972;
CC       O14965; P04198: MYCN; NbExp=12; IntAct=EBI-448680, EBI-878369;
CC       O14965; P06748: NPM1; NbExp=3; IntAct=EBI-448680, EBI-78579;
CC       O14965; P53350: PLK1; NbExp=4; IntAct=EBI-448680, EBI-476768;
CC       O14965; P23468: PTPRD; NbExp=2; IntAct=EBI-448680, EBI-2682990;
CC       O14965; Q96R06: SPAG5; NbExp=3; IntAct=EBI-448680, EBI-413317;
CC       O14965; O15350: TP73; NbExp=11; IntAct=EBI-448680, EBI-389606;
CC       O14965; Q9ULW0: TPX2; NbExp=8; IntAct=EBI-448680, EBI-1037322;
CC       O14965; Q8VDQ8: Sirt2; Xeno; NbExp=5; IntAct=EBI-448680, EBI-911012;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome {ECO:0000269|PubMed:12576638,
CC       ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17229885,
CC       ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:19357306,
CC       ECO:0000269|PubMed:21225229, ECO:0000269|PubMed:22014574,
CC       ECO:0000269|PubMed:23213400, ECO:0000269|PubMed:25657325,
CC       ECO:0000269|PubMed:30538148, ECO:0000269|PubMed:9153231}. Cytoplasm,
CC       cytoskeleton, spindle pole {ECO:0000269|PubMed:12576638,
CC       ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17726514,
CC       ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:25657325,
CC       ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:9153231,
CC       ECO:0000269|PubMed:9606188}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome, centriole
CC       {ECO:0000250|UniProtKB:P97477}. Cell projection, neuron projection
CC       {ECO:0000250|UniProtKB:P97477}. Cell projection, cilium
CC       {ECO:0000269|PubMed:17604723}. Cytoplasm, cytoskeleton, cilium basal
CC       body {ECO:0000269|PubMed:17604723}. Basolateral cell membrane
CC       {ECO:0000250|UniProtKB:F1PNY0}. Note=Detected at the neurite hillock in
CC       developing neurons (By similarity). Localizes at the centrosome in
CC       mitotic cells from early prophase until telophase, but also localizes
CC       to the spindle pole MTs from prophase to anaphase (PubMed:9606188,
CC       PubMed:17229885, PubMed:21225229). Colocalized with SIRT2 at centrosome
CC       (PubMed:22014574). Moves to the midbody during both telophase and
CC       cytokinesis (PubMed:17726514). Associates with both the pericentriolar
CC       material (PCM) and centrioles (PubMed:22014574). The localization to
CC       the spindle poles is regulated by AAAS (PubMed:26246606).
CC       {ECO:0000250|UniProtKB:P97477, ECO:0000269|PubMed:17229885,
CC       ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:21225229,
CC       ECO:0000269|PubMed:22014574, ECO:0000269|PubMed:26246606,
CC       ECO:0000269|PubMed:9606188}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in testis and weakly in skeletal
CC       muscle, thymus and spleen. Also highly expressed in colon, ovarian,
CC       prostate, neuroblastoma, breast and cervical cancer cell lines.
CC   -!- INDUCTION: Expression is cell-cycle regulated, low in G1/S, accumulates
CC       during G2/M, and decreases rapidly after. {ECO:0000269|PubMed:11790771,
CC       ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:15987997,
CC       ECO:0000269|PubMed:9153231, ECO:0000269|PubMed:9606188}.
CC   -!- PTM: Activated by phosphorylation at Thr-288; this brings about a
CC       change in the conformation of the activation segment. Phosphorylation
CC       at Thr-288 varies during the cell cycle and is highest during M phase.
CC       Autophosphorylated at Thr-288 upon TPX2 binding. Thr-288 can be
CC       phosphorylated by several kinases, including PAK and PKA. Protein
CC       phosphatase type 1 (PP1) binds AURKA and inhibits its activity by
CC       dephosphorylating Thr-288 during mitosis. Phosphorylation at Ser-342
CC       decreases the kinase activity. PPP2CA controls degradation by
CC       dephosphorylating Ser-51 at the end of mitosis.
CC       {ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964,
CC       ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582,
CC       ECO:0000269|PubMed:14580337, ECO:0000269|PubMed:16246726,
CC       ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:18662907,
CC       ECO:0000269|PubMed:19668197}.
CC   -!- PTM: Ubiquitinated by the E3 ubiquitin-protein ligase complex
CC       SCF(FBXL7) during mitosis, leading to its degradation by the proteasome
CC       (By similarity). Ubiquitinated by CHFR, leading to its degradation by
CC       the proteasome (By similarity). Ubiquitinated by the anaphase-promoting
CC       complex (APC), leading to its degradation by the proteasome
CC       (PubMed:10851084, PubMed:11039908). Ubiquitinated by the CUL3-KLHL18
CC       ligase leading to its activation at the centrosome which is required
CC       for initiating mitotic entry (PubMed:23213400). Ubiquitination mediated
CC       by CUL3-KLHL18 ligase does not lead to its degradation by the
CC       proteasome (PubMed:23213400). {ECO:0000250|UniProtKB:P97477,
CC       ECO:0000269|PubMed:10851084, ECO:0000269|PubMed:11039908,
CC       ECO:0000269|PubMed:23213400}.
CC   -!- MISCELLANEOUS: Centrosome amplification can occur when the cycles are
CC       uncoupled, and this amplification is associated with cancer and with an
CC       increase in the levels of chromosomal instability.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. Aurora subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- CAUTION: Authors initially considered AURKA/STK6 and STK15 as 2
CC       different proteins (PubMed:9771714). It is clear that they are the same
CC       protein. {ECO:0000305|PubMed:9771714}.
CC   -!- CAUTION: An article that concluded that AURKA-mediated phosphorylation
CC       of BRCA1 'Ser-308' plays a role in the normal cell cycle G2/M
CC       transition was withdrawn due to data manipulation of flow cytometry
CC       data. {ECO:0000305|PubMed:14990569, ECO:0000305|PubMed:26341884}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA23592.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AURKAID730ch20q13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D84212; BAA23592.1; ALT_FRAME; mRNA.
DR   EMBL; AF008551; AAC12708.1; -; mRNA.
DR   EMBL; AF011467; AAC23448.1; -; Genomic_DNA.
DR   EMBL; AF011468; AAC63902.1; -; mRNA.
DR   EMBL; AF195947; AAF29508.1; -; Genomic_DNA.
DR   EMBL; AF195942; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195943; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195944; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195945; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AF195946; AAF29508.1; JOINED; Genomic_DNA.
DR   EMBL; AL121914; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471077; EAW75550.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75551.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75552.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75553.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75554.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75555.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75556.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75557.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75558.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75559.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75561.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75562.1; -; Genomic_DNA.
DR   EMBL; BC001280; AAH01280.1; -; mRNA.
DR   EMBL; BC002499; AAH02499.1; -; mRNA.
DR   EMBL; BC006423; AAH06423.1; -; mRNA.
DR   EMBL; BC027464; AAH27464.1; -; mRNA.
DR   CCDS; CCDS13451.1; -.
DR   PIR; JC5974; JC5974.
DR   RefSeq; NP_001310232.1; NM_001323303.1.
DR   RefSeq; NP_001310233.1; NM_001323304.1.
DR   RefSeq; NP_001310234.1; NM_001323305.1.
DR   RefSeq; NP_003591.2; NM_003600.3.
DR   RefSeq; NP_940835.1; NM_198433.2.
DR   RefSeq; NP_940836.1; NM_198434.2.
DR   RefSeq; NP_940837.1; NM_198435.2.
DR   RefSeq; NP_940838.1; NM_198436.2.
DR   RefSeq; NP_940839.1; NM_198437.2.
DR   RefSeq; XP_016883524.1; XM_017028035.1.
DR   PDB; 1MQ4; X-ray; 1.90 A; A=125-391.
DR   PDB; 1MUO; X-ray; 2.90 A; A=107-403.
DR   PDB; 1OL5; X-ray; 2.50 A; A=122-403.
DR   PDB; 1OL6; X-ray; 3.00 A; A=122-403.
DR   PDB; 1OL7; X-ray; 2.75 A; A=122-403.
DR   PDB; 2BMC; X-ray; 2.60 A; A/B/C/D/E/F=100-403.
DR   PDB; 2C6D; X-ray; 2.20 A; A=124-398.
DR   PDB; 2C6E; X-ray; 2.10 A; A/B=123-401.
DR   PDB; 2DWB; X-ray; 2.50 A; A=122-403.
DR   PDB; 2J4Z; X-ray; 2.00 A; A/B=100-403.
DR   PDB; 2J50; X-ray; 3.00 A; A/B=126-403.
DR   PDB; 2NP8; X-ray; 2.25 A; A=125-391.
DR   PDB; 2W1C; X-ray; 3.24 A; A=122-389.
DR   PDB; 2W1D; X-ray; 2.97 A; A=122-389.
DR   PDB; 2W1E; X-ray; 2.93 A; A=122-389.
DR   PDB; 2W1F; X-ray; 2.85 A; A=122-389.
DR   PDB; 2W1G; X-ray; 2.71 A; A=122-389.
DR   PDB; 2WQE; X-ray; 2.50 A; A=127-388.
DR   PDB; 2WTV; X-ray; 2.40 A; A/B/C/D=122-403.
DR   PDB; 2WTW; X-ray; 3.30 A; A=122-403.
DR   PDB; 2X6D; X-ray; 2.80 A; A=122-403.
DR   PDB; 2X6E; X-ray; 3.35 A; A=122-403.
DR   PDB; 2X81; X-ray; 2.91 A; A=126-391.
DR   PDB; 2XNE; X-ray; 2.80 A; A=122-392.
DR   PDB; 2XNG; X-ray; 2.60 A; A=122-403.
DR   PDB; 2XRU; X-ray; 2.90 A; A=126-403.
DR   PDB; 3COH; X-ray; 2.70 A; A/B=124-391.
DR   PDB; 3E5A; X-ray; 2.30 A; A=125-391.
DR   PDB; 3EFW; X-ray; 2.29 A; A/B=125-391.
DR   PDB; 3FDN; X-ray; 1.90 A; A=123-401.
DR   PDB; 3H0Y; X-ray; 2.50 A; A=124-391.
DR   PDB; 3H0Z; X-ray; 2.92 A; A/B/C=124-391.
DR   PDB; 3H10; X-ray; 2.20 A; A/B/D=124-391.
DR   PDB; 3HA6; X-ray; 2.36 A; A=125-391.
DR   PDB; 3K5U; X-ray; 2.35 A; A=123-401.
DR   PDB; 3LAU; X-ray; 2.10 A; A=125-399.
DR   PDB; 3M11; X-ray; 2.75 A; A=123-401.
DR   PDB; 3MYG; X-ray; 2.40 A; A=125-391.
DR   PDB; 3NRM; X-ray; 3.05 A; A=126-403.
DR   PDB; 3O50; X-ray; 2.00 A; A/B=125-391.
DR   PDB; 3O51; X-ray; 3.20 A; A=125-391.
DR   PDB; 3P9J; X-ray; 2.80 A; A=125-391.
DR   PDB; 3QBN; X-ray; 3.50 A; A=124-403.
DR   PDB; 3R21; X-ray; 2.90 A; A=126-391.
DR   PDB; 3R22; X-ray; 2.90 A; A=126-391.
DR   PDB; 3UNZ; X-ray; 2.80 A; A/B=123-401.
DR   PDB; 3UO4; X-ray; 2.45 A; A=123-401.
DR   PDB; 3UO5; X-ray; 2.70 A; A=123-401.
DR   PDB; 3UO6; X-ray; 2.80 A; A/B=123-401.
DR   PDB; 3UOD; X-ray; 2.50 A; A=123-401.
DR   PDB; 3UOH; X-ray; 2.80 A; A/B=123-401.
DR   PDB; 3UOJ; X-ray; 2.90 A; A/B=123-401.
DR   PDB; 3UOK; X-ray; 2.95 A; A/B=123-401.
DR   PDB; 3UOL; X-ray; 2.40 A; A/B=123-401.
DR   PDB; 3UP2; X-ray; 2.30 A; A=123-401.
DR   PDB; 3UP7; X-ray; 3.05 A; A=123-401.
DR   PDB; 3VAP; X-ray; 2.66 A; A=125-391.
DR   PDB; 3W10; X-ray; 2.70 A; A=126-403.
DR   PDB; 3W16; X-ray; 2.80 A; A=126-403.
DR   PDB; 3W18; X-ray; 2.50 A; A/B=126-403.
DR   PDB; 3W2C; X-ray; 2.45 A; A/C/E/G=128-388.
DR   PDB; 4B0G; X-ray; 2.50 A; A=122-403.
DR   PDB; 4BN1; X-ray; 2.50 A; A=122-403.
DR   PDB; 4BYI; X-ray; 2.60 A; A=122-403.
DR   PDB; 4BYJ; X-ray; 2.75 A; A=122-403.
DR   PDB; 4C3P; X-ray; 2.69 A; A/D=122-403.
DR   PDB; 4C3R; X-ray; 2.79 A; A=122-403.
DR   PDB; 4CEG; X-ray; 2.10 A; A=122-403.
DR   PDB; 4DEA; X-ray; 2.45 A; A=123-401.
DR   PDB; 4DEB; X-ray; 3.05 A; A=123-401.
DR   PDB; 4DED; X-ray; 3.05 A; A=123-401.
DR   PDB; 4DEE; X-ray; 2.30 A; A=123-401.
DR   PDB; 4DHF; X-ray; 2.80 A; A/B=126-391.
DR   PDB; 4J8M; X-ray; 1.85 A; A=123-401.
DR   PDB; 4J8N; X-ray; 3.14 A; A/B/C/D=123-401.
DR   PDB; 4JAI; X-ray; 3.20 A; A=122-396.
DR   PDB; 4JAJ; X-ray; 2.70 A; A=122-396.
DR   PDB; 4JBO; X-ray; 2.49 A; A=123-401.
DR   PDB; 4JBP; X-ray; 2.45 A; A=123-401.
DR   PDB; 4JBQ; X-ray; 2.30 A; A=123-401.
DR   PDB; 4O0S; X-ray; 2.50 A; A=122-403.
DR   PDB; 4O0U; X-ray; 2.60 A; A=122-403.
DR   PDB; 4O0W; X-ray; 2.60 A; A=122-403.
DR   PDB; 4PRJ; X-ray; 2.80 A; A=124-391.
DR   PDB; 4UYN; X-ray; 1.90 A; A=125-399.
DR   PDB; 4UZD; X-ray; 3.20 A; A/B=125-399.
DR   PDB; 4UZH; X-ray; 2.00 A; A=125-399.
DR   PDB; 4ZS0; X-ray; 3.00 A; A=122-403.
DR   PDB; 4ZTQ; X-ray; 2.80 A; A=122-403.
DR   PDB; 4ZTR; X-ray; 2.85 A; A=122-403.
DR   PDB; 4ZTS; X-ray; 2.90 A; A=122-403.
DR   PDB; 5AAD; X-ray; 3.10 A; A=122-403.
DR   PDB; 5AAE; X-ray; 3.11 A; A=122-403.
DR   PDB; 5AAF; X-ray; 2.78 A; A=122-403.
DR   PDB; 5AAG; X-ray; 2.85 A; A=122-403.
DR   PDB; 5DN3; X-ray; 2.05 A; A=125-391.
DR   PDB; 5DNR; X-ray; 1.95 A; A=125-391.
DR   PDB; 5DOS; X-ray; 2.98 A; A=126-390.
DR   PDB; 5DPV; X-ray; 2.29 A; A=126-390.
DR   PDB; 5DR2; X-ray; 2.46 A; A=128-390.
DR   PDB; 5DR6; X-ray; 2.53 A; A=126-390.
DR   PDB; 5DR9; X-ray; 2.47 A; A=126-390.
DR   PDB; 5DRD; X-ray; 2.13 A; A=126-390.
DR   PDB; 5DT0; X-ray; 2.15 A; A=126-390.
DR   PDB; 5DT3; X-ray; 2.33 A; A=126-390.
DR   PDB; 5DT4; X-ray; 2.86 A; A=126-390.
DR   PDB; 5EW9; X-ray; 2.18 A; A=123-390.
DR   PDB; 5G15; X-ray; 2.06 A; A=122-403.
DR   PDB; 5G1X; X-ray; 1.72 A; A=122-403.
DR   PDB; 5L8J; X-ray; 1.68 A; A=122-403.
DR   PDB; 5L8K; X-ray; 1.79 A; A=122-403.
DR   PDB; 5L8L; X-ray; 1.67 A; A=122-403.
DR   PDB; 5LXM; X-ray; 2.08 A; A=122-403.
DR   PDB; 5OBJ; X-ray; 2.90 A; A=125-391.
DR   PDB; 5OBR; X-ray; 2.62 A; A=125-391.
DR   PDB; 5ODT; X-ray; 2.02 A; A=122-403.
DR   PDB; 5ONE; X-ray; 2.60 A; A=122-403.
DR   PDB; 5ORL; X-ray; 1.69 A; A=127-391.
DR   PDB; 5ORN; X-ray; 2.19 A; A=127-391.
DR   PDB; 5ORO; X-ray; 2.12 A; A=127-391.
DR   PDB; 5ORP; X-ray; 2.19 A; A=127-391.
DR   PDB; 5ORR; X-ray; 2.09 A; A=127-391.
DR   PDB; 5ORS; X-ray; 1.98 A; A=127-391.
DR   PDB; 5ORT; X-ray; 2.56 A; A=127-391.
DR   PDB; 5ORV; X-ray; 1.88 A; A=127-391.
DR   PDB; 5ORW; X-ray; 2.00 A; A=127-391.
DR   PDB; 5ORX; X-ray; 1.88 A; A=127-391.
DR   PDB; 5ORY; X-ray; 1.99 A; A=127-391.
DR   PDB; 5ORZ; X-ray; 1.92 A; A=127-391.
DR   PDB; 5OS0; X-ray; 1.74 A; A=127-391.
DR   PDB; 5OS1; X-ray; 1.90 A; A=127-391.
DR   PDB; 5OS2; X-ray; 1.92 A; A=127-391.
DR   PDB; 5OS3; X-ray; 1.81 A; A=127-391.
DR   PDB; 5OS4; X-ray; 1.88 A; A=127-391.
DR   PDB; 5OS5; X-ray; 1.74 A; A=125-392.
DR   PDB; 5OS6; X-ray; 2.20 A; A=127-391.
DR   PDB; 5OSD; X-ray; 1.99 A; A=125-391.
DR   PDB; 5OSE; X-ray; 1.90 A; A=127-391.
DR   PDB; 5OSF; X-ray; 1.89 A; A=127-391.
DR   PDB; 5ZAN; X-ray; 2.85 A; A=123-403.
DR   PDB; 6C2R; X-ray; 1.96 A; A=125-391.
DR   PDB; 6C2T; X-ray; 1.73 A; A=125-391.
DR   PDB; 6C83; X-ray; 2.55 A; A/B=122-403.
DR   PDB; 6CPE; X-ray; 2.45 A; A=122-403.
DR   PDB; 6CPF; X-ray; 2.30 A; A=122-403.
DR   PDB; 6CPG; X-ray; 2.80 A; A/D=122-403.
DR   PDB; 6GRA; X-ray; 2.60 A; A=122-403.
DR   PDB; 6HJJ; X-ray; 2.13 A; A=122-403.
DR   PDB; 6HJK; X-ray; 2.40 A; A=122-403.
DR   PDB; 6I2U; X-ray; 2.50 A; A=122-403.
DR   PDB; 6R49; X-ray; 2.21 A; A=122-403.
DR   PDB; 6R4A; X-ray; 1.94 A; A=122-403.
DR   PDB; 6R4B; X-ray; 2.15 A; A=122-403.
DR   PDB; 6R4C; X-ray; 2.04 A; A=122-403.
DR   PDB; 6R4D; X-ray; 2.01 A; A=122-403.
DR   PDB; 6VPG; X-ray; 2.64 A; A=117-389.
DR   PDB; 6VPH; X-ray; 2.14 A; A=117-389.
DR   PDB; 6VPI; X-ray; 2.00 A; A=117-389.
DR   PDB; 6VPJ; X-ray; 2.10 A; A=117-389.
DR   PDB; 6VPL; X-ray; 1.86 A; A/B=117-389.
DR   PDB; 6VPM; X-ray; 1.58 A; A/B=117-389.
DR   PDB; 6XKA; X-ray; 2.65 A; A=117-389.
DR   PDB; 6Z4Y; X-ray; 2.25 A; A=122-403.
DR   PDB; 7AYH; X-ray; 2.80 A; A=122-403.
DR   PDB; 7AYI; X-ray; 2.86 A; A=122-403.
DR   PDB; 7O2V; X-ray; 3.10 A; A=116-403.
DR   PDBsum; 1MQ4; -.
DR   PDBsum; 1MUO; -.
DR   PDBsum; 1OL5; -.
DR   PDBsum; 1OL6; -.
DR   PDBsum; 1OL7; -.
DR   PDBsum; 2BMC; -.
DR   PDBsum; 2C6D; -.
DR   PDBsum; 2C6E; -.
DR   PDBsum; 2DWB; -.
DR   PDBsum; 2J4Z; -.
DR   PDBsum; 2J50; -.
DR   PDBsum; 2NP8; -.
DR   PDBsum; 2W1C; -.
DR   PDBsum; 2W1D; -.
DR   PDBsum; 2W1E; -.
DR   PDBsum; 2W1F; -.
DR   PDBsum; 2W1G; -.
DR   PDBsum; 2WQE; -.
DR   PDBsum; 2WTV; -.
DR   PDBsum; 2WTW; -.
DR   PDBsum; 2X6D; -.
DR   PDBsum; 2X6E; -.
DR   PDBsum; 2X81; -.
DR   PDBsum; 2XNE; -.
DR   PDBsum; 2XNG; -.
DR   PDBsum; 2XRU; -.
DR   PDBsum; 3COH; -.
DR   PDBsum; 3E5A; -.
DR   PDBsum; 3EFW; -.
DR   PDBsum; 3FDN; -.
DR   PDBsum; 3H0Y; -.
DR   PDBsum; 3H0Z; -.
DR   PDBsum; 3H10; -.
DR   PDBsum; 3HA6; -.
DR   PDBsum; 3K5U; -.
DR   PDBsum; 3LAU; -.
DR   PDBsum; 3M11; -.
DR   PDBsum; 3MYG; -.
DR   PDBsum; 3NRM; -.
DR   PDBsum; 3O50; -.
DR   PDBsum; 3O51; -.
DR   PDBsum; 3P9J; -.
DR   PDBsum; 3QBN; -.
DR   PDBsum; 3R21; -.
DR   PDBsum; 3R22; -.
DR   PDBsum; 3UNZ; -.
DR   PDBsum; 3UO4; -.
DR   PDBsum; 3UO5; -.
DR   PDBsum; 3UO6; -.
DR   PDBsum; 3UOD; -.
DR   PDBsum; 3UOH; -.
DR   PDBsum; 3UOJ; -.
DR   PDBsum; 3UOK; -.
DR   PDBsum; 3UOL; -.
DR   PDBsum; 3UP2; -.
DR   PDBsum; 3UP7; -.
DR   PDBsum; 3VAP; -.
DR   PDBsum; 3W10; -.
DR   PDBsum; 3W16; -.
DR   PDBsum; 3W18; -.
DR   PDBsum; 3W2C; -.
DR   PDBsum; 4B0G; -.
DR   PDBsum; 4BN1; -.
DR   PDBsum; 4BYI; -.
DR   PDBsum; 4BYJ; -.
DR   PDBsum; 4C3P; -.
DR   PDBsum; 4C3R; -.
DR   PDBsum; 4CEG; -.
DR   PDBsum; 4DEA; -.
DR   PDBsum; 4DEB; -.
DR   PDBsum; 4DED; -.
DR   PDBsum; 4DEE; -.
DR   PDBsum; 4DHF; -.
DR   PDBsum; 4J8M; -.
DR   PDBsum; 4J8N; -.
DR   PDBsum; 4JAI; -.
DR   PDBsum; 4JAJ; -.
DR   PDBsum; 4JBO; -.
DR   PDBsum; 4JBP; -.
DR   PDBsum; 4JBQ; -.
DR   PDBsum; 4O0S; -.
DR   PDBsum; 4O0U; -.
DR   PDBsum; 4O0W; -.
DR   PDBsum; 4PRJ; -.
DR   PDBsum; 4UYN; -.
DR   PDBsum; 4UZD; -.
DR   PDBsum; 4UZH; -.
DR   PDBsum; 4ZS0; -.
DR   PDBsum; 4ZTQ; -.
DR   PDBsum; 4ZTR; -.
DR   PDBsum; 4ZTS; -.
DR   PDBsum; 5AAD; -.
DR   PDBsum; 5AAE; -.
DR   PDBsum; 5AAF; -.
DR   PDBsum; 5AAG; -.
DR   PDBsum; 5DN3; -.
DR   PDBsum; 5DNR; -.
DR   PDBsum; 5DOS; -.
DR   PDBsum; 5DPV; -.
DR   PDBsum; 5DR2; -.
DR   PDBsum; 5DR6; -.
DR   PDBsum; 5DR9; -.
DR   PDBsum; 5DRD; -.
DR   PDBsum; 5DT0; -.
DR   PDBsum; 5DT3; -.
DR   PDBsum; 5DT4; -.
DR   PDBsum; 5EW9; -.
DR   PDBsum; 5G15; -.
DR   PDBsum; 5G1X; -.
DR   PDBsum; 5L8J; -.
DR   PDBsum; 5L8K; -.
DR   PDBsum; 5L8L; -.
DR   PDBsum; 5LXM; -.
DR   PDBsum; 5OBJ; -.
DR   PDBsum; 5OBR; -.
DR   PDBsum; 5ODT; -.
DR   PDBsum; 5ONE; -.
DR   PDBsum; 5ORL; -.
DR   PDBsum; 5ORN; -.
DR   PDBsum; 5ORO; -.
DR   PDBsum; 5ORP; -.
DR   PDBsum; 5ORR; -.
DR   PDBsum; 5ORS; -.
DR   PDBsum; 5ORT; -.
DR   PDBsum; 5ORV; -.
DR   PDBsum; 5ORW; -.
DR   PDBsum; 5ORX; -.
DR   PDBsum; 5ORY; -.
DR   PDBsum; 5ORZ; -.
DR   PDBsum; 5OS0; -.
DR   PDBsum; 5OS1; -.
DR   PDBsum; 5OS2; -.
DR   PDBsum; 5OS3; -.
DR   PDBsum; 5OS4; -.
DR   PDBsum; 5OS5; -.
DR   PDBsum; 5OS6; -.
DR   PDBsum; 5OSD; -.
DR   PDBsum; 5OSE; -.
DR   PDBsum; 5OSF; -.
DR   PDBsum; 5ZAN; -.
DR   PDBsum; 6C2R; -.
DR   PDBsum; 6C2T; -.
DR   PDBsum; 6C83; -.
DR   PDBsum; 6CPE; -.
DR   PDBsum; 6CPF; -.
DR   PDBsum; 6CPG; -.
DR   PDBsum; 6GRA; -.
DR   PDBsum; 6HJJ; -.
DR   PDBsum; 6HJK; -.
DR   PDBsum; 6I2U; -.
DR   PDBsum; 6R49; -.
DR   PDBsum; 6R4A; -.
DR   PDBsum; 6R4B; -.
DR   PDBsum; 6R4C; -.
DR   PDBsum; 6R4D; -.
DR   PDBsum; 6VPG; -.
DR   PDBsum; 6VPH; -.
DR   PDBsum; 6VPI; -.
DR   PDBsum; 6VPJ; -.
DR   PDBsum; 6VPL; -.
DR   PDBsum; 6VPM; -.
DR   PDBsum; 6XKA; -.
DR   PDBsum; 6Z4Y; -.
DR   PDBsum; 7AYH; -.
DR   PDBsum; 7AYI; -.
DR   PDBsum; 7O2V; -.
DR   AlphaFoldDB; O14965; -.
DR   SMR; O14965; -.
DR   BioGRID; 112666; 658.
DR   CORUM; O14965; -.
DR   DIP; DIP-33068N; -.
DR   ELM; O14965; -.
DR   IntAct; O14965; 184.
DR   MINT; O14965; -.
DR   STRING; 9606.ENSP00000216911; -.
DR   BindingDB; O14965; -.
DR   ChEMBL; CHEMBL4722; -.
DR   DrugBank; DB07362; 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea.
DR   DrugBank; DB07360; 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea.
DR   DrugBank; DB08065; 2-(1H-pyrazol-3-yl)-1H-benzimidazole.
DR   DrugBank; DB07186; 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE.
DR   DrugBank; DB07266; AKI-001.
DR   DrugBank; DB05220; Alisertib.
DR   DrugBank; DB05169; AT9283.
DR   DrugBank; DB06347; Cenisertib.
DR   DrugBank; DB05198; CYC116.
DR   DrugBank; DB06486; Enzastaurin.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB13061; MLN8054.
DR   DrugBank; DB08066; N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE.
DR   DrugBank; DB07801; N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide.
DR   DrugBank; DB07545; N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE.
DR   DrugBank; DB02482; Phosphonothreonine.
DR   DrugBank; DB06134; SNS-314.
DR   DrugCentral; O14965; -.
DR   GuidetoPHARMACOLOGY; 1936; -.
DR   iPTMnet; O14965; -.
DR   PhosphoSitePlus; O14965; -.
DR   BioMuta; AURKA; -.
DR   CPTAC; CPTAC-1341; -.
DR   EPD; O14965; -.
DR   jPOST; O14965; -.
DR   MassIVE; O14965; -.
DR   MaxQB; O14965; -.
DR   PaxDb; O14965; -.
DR   PeptideAtlas; O14965; -.
DR   PRIDE; O14965; -.
DR   ProteomicsDB; 48339; -.
DR   ABCD; O14965; 1 sequenced antibody.
DR   Antibodypedia; 1129; 1075 antibodies from 46 providers.
DR   DNASU; 6790; -.
DR   Ensembl; ENST00000312783.10; ENSP00000321591.6; ENSG00000087586.18.
DR   Ensembl; ENST00000347343.6; ENSP00000216911.2; ENSG00000087586.18.
DR   Ensembl; ENST00000371356.6; ENSP00000360407.2; ENSG00000087586.18.
DR   Ensembl; ENST00000395911.5; ENSP00000379247.1; ENSG00000087586.18.
DR   Ensembl; ENST00000395913.7; ENSP00000379249.3; ENSG00000087586.18.
DR   Ensembl; ENST00000395914.5; ENSP00000379250.1; ENSG00000087586.18.
DR   Ensembl; ENST00000395915.8; ENSP00000379251.3; ENSG00000087586.18.
DR   GeneID; 6790; -.
DR   KEGG; hsa:6790; -.
DR   MANE-Select; ENST00000395915.8; ENSP00000379251.3; NM_198437.3; NP_940839.1.
DR   UCSC; uc002xxe.1; human.
DR   CTD; 6790; -.
DR   DisGeNET; 6790; -.
DR   GeneCards; AURKA; -.
DR   HGNC; HGNC:11393; AURKA.
DR   HPA; ENSG00000087586; Tissue enhanced (lymphoid tissue, testis).
DR   MalaCards; AURKA; -.
DR   MIM; 603072; gene.
DR   neXtProt; NX_O14965; -.
DR   OpenTargets; ENSG00000087586; -.
DR   PharmGKB; PA36201; -.
DR   VEuPathDB; HostDB:ENSG00000087586; -.
DR   eggNOG; KOG0580; Eukaryota.
DR   GeneTree; ENSGT00940000154900; -.
DR   InParanoid; O14965; -.
DR   OrthoDB; 954262at2759; -.
DR   PhylomeDB; O14965; -.
DR   TreeFam; TF105331; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; O14965; -.
DR   Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins.
DR   Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-8854050; FBXL7 down-regulates AURKA during mitotic entry and in early mitosis.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   Reactome; R-HSA-8854521; Interaction between PHLDA1 and AURKA.
DR   SignaLink; O14965; -.
DR   SIGNOR; O14965; -.
DR   BioGRID-ORCS; 6790; 685 hits in 1128 CRISPR screens.
DR   ChiTaRS; AURKA; human.
DR   EvolutionaryTrace; O14965; -.
DR   GeneWiki; Aurora_A_kinase; -.
DR   GenomeRNAi; 6790; -.
DR   Pharos; O14965; Tchem.
DR   PRO; PR:O14965; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; O14965; protein.
DR   Bgee; ENSG00000087586; Expressed in oocyte and 158 other tissues.
DR   ExpressionAtlas; O14965; baseline and differential.
DR   Genevisible; O14965; HS.
DR   GO; GO:0043203; C:axon hillock; IEA:Ensembl.
DR   GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0032133; C:chromosome passenger complex; IBA:GO_Central.
DR   GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0042585; C:germinal vesicle; IEA:Ensembl.
DR   GO; GO:0072687; C:meiotic spindle; IEA:Ensembl.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL.
DR   GO; GO:0030496; C:midbody; TAS:UniProtKB.
DR   GO; GO:0072686; C:mitotic spindle; IDA:HPA.
DR   GO; GO:0097431; C:mitotic spindle pole; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0045120; C:pronucleus; IEA:Ensembl.
DR   GO; GO:0005819; C:spindle; TAS:UniProtKB.
DR   GO; GO:0051233; C:spindle midzone; IBA:GO_Central.
DR   GO; GO:0031616; C:spindle pole centrosome; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0035174; F:histone serine kinase activity; IBA:GO_Central.
DR   GO; GO:0140677; F:molecular function activator activity; EXP:DisProt.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:CAFA.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IEA:Ensembl.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0051642; P:centrosome localization; IEA:Ensembl.
DR   GO; GO:0061523; P:cilium disassembly; IMP:UniProtKB.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0097421; P:liver regeneration; IDA:MGI.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:ProtInc.
DR   GO; GO:0007100; P:mitotic centrosome separation; IEA:Ensembl.
DR   GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB.
DR   GO; GO:1990138; P:neuron projection extension; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0090141; P:positive regulation of mitochondrial fission; IMP:UniProtKB.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; TAS:UniProtKB.
DR   GO; GO:1900195; P:positive regulation of oocyte maturation; IEA:Ensembl.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0071539; P:protein localization to centrosome; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046605; P:regulation of centrosome cycle; TAS:UniProtKB.
DR   GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central.
DR   GO; GO:0010389; P:regulation of G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0009611; P:response to wounding; IDA:MGI.
DR   GO; GO:0007057; P:spindle assembly involved in female meiosis I; IEA:Ensembl.
DR   GO; GO:0007051; P:spindle organization; IMP:UniProtKB.
DR   CDD; cd14116; STKc_Aurora-A; 1.
DR   InterPro; IPR030616; Aur.
DR   InterPro; IPR030611; AURKA.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24350; PTHR24350; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell cycle; Cell division; Cell membrane;
KW   Cell projection; Cilium; Cilium biogenesis/degradation; Cytoplasm;
KW   Cytoskeleton; Isopeptide bond; Kinase; Membrane; Microtubule; Mitosis;
KW   Nucleotide-binding; Phosphoprotein; Proto-oncogene; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..403
FT                   /note="Aurora kinase A"
FT                   /id="PRO_0000086692"
FT   DOMAIN          133..383
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..125
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          280..293
FT                   /note="Activation segment"
FT                   /evidence="ECO:0000269|PubMed:14580337"
FT   COMPBIAS        28..105
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        256
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027,
FT                   ECO:0000269|PubMed:14580337"
FT   BINDING         143
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27837025,
FT                   ECO:0007744|PDB:5G1X"
FT   BINDING         162
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27837025,
FT                   ECO:0007744|PDB:5G1X"
FT   BINDING         211..213
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27837025,
FT                   ECO:0007744|PDB:5G1X"
FT   BINDING         260..261
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27837025,
FT                   ECO:0007744|PDB:5G1X"
FT   BINDING         274
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:27837025,
FT                   ECO:0007744|PDB:5G1X"
FT   MOD_RES         41
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         51
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:17229885"
FT   MOD_RES         287
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:14580337,
FT                   ECO:0000269|PubMed:19668197"
FT   MOD_RES         288
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:11039908,
FT                   ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:14580337,
FT                   ECO:0000269|PubMed:16246726, ECO:0000269|PubMed:18662907,
FT                   ECO:0000269|PubMed:19668197, ECO:0000269|PubMed:26246606"
FT   MOD_RES         342
FT                   /note="Phosphoserine; by PKA and PAK"
FT                   /evidence="ECO:0000269|PubMed:16246726"
FT   CROSSLNK        258
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         11
FT                   /note="G -> R (in dbSNP:rs6069717)"
FT                   /id="VAR_030840"
FT   VARIANT         31
FT                   /note="F -> I (in dbSNP:rs2273535)"
FT                   /evidence="ECO:0000269|PubMed:15867347,
FT                   ECO:0000269|PubMed:16011022, ECO:0000269|PubMed:16762494,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9771714"
FT                   /id="VAR_030841"
FT   VARIANT         50
FT                   /note="P -> L (in dbSNP:rs34572020)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041127"
FT   VARIANT         57
FT                   /note="I -> V (increased kinase activity; dbSNP:rs1047972)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:15867347, ECO:0000269|PubMed:16011022,
FT                   ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9153231,
FT                   ECO:0000269|PubMed:9514916, ECO:0000269|PubMed:9771714"
FT                   /id="VAR_030842"
FT   VARIANT         104
FT                   /note="S -> L (in dbSNP:rs2230743)"
FT                   /id="VAR_061745"
FT   VARIANT         155
FT                   /note="S -> R (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; reduces interaction with TPX2)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:19801554"
FT                   /id="VAR_041128"
FT   VARIANT         174
FT                   /note="V -> M (in a metastatic melanoma sample; somatic
FT                   mutation; constitutively enhanced kinase activity)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:19801554"
FT                   /id="VAR_041129"
FT   VARIANT         373
FT                   /note="M -> V (in dbSNP:rs33923703)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041130"
FT   MUTAGEN         162
FT                   /note="K->R: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:14702041"
FT   MUTAGEN         165
FT                   /note="F->A: Decreases the interaction with phosphatase
FT                   type 1 isoforms."
FT                   /evidence="ECO:0000269|PubMed:11551964"
FT   MUTAGEN         198
FT                   /note="G->N: Reduces interaction with TPX2. Reduces kinase
FT                   activity tenfold. Promotes interaction with the AURKB
FT                   binding partners INCENP and BIRC5 that are normally not
FT                   bound by AURKA."
FT                   /evidence="ECO:0000269|PubMed:19357306"
FT   MUTAGEN         205
FT                   /note="R->A: Reduces ubiquitination and proteasomal
FT                   degradation."
FT                   /evidence="ECO:0000269|PubMed:10851084"
FT   MUTAGEN         274
FT                   /note="D->N: Abolishes cilia disassembly and kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:14580337,
FT                   ECO:0000269|PubMed:17604723"
FT   MUTAGEN         287
FT                   /note="T->A: No direct effect on catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:19668197"
FT   MUTAGEN         287
FT                   /note="T->E: Enhances interaction with TPX2."
FT                   /evidence="ECO:0000269|PubMed:19668197"
FT   MUTAGEN         288
FT                   /note="T->A: Reduces cilia disassembly and kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:17604723"
FT   MUTAGEN         288
FT                   /note="T->D: Mimics phosphorylation state and increases
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11039908"
FT   MUTAGEN         290
FT                   /note="C->A: Enhances stability; when associated with
FT                   A-393."
FT                   /evidence="ECO:0000269|PubMed:27837025"
FT   MUTAGEN         334
FT                   /note="Y->A: Reduces binding to MYCN."
FT                   /evidence="ECO:0000269|PubMed:27837025"
FT   MUTAGEN         335
FT                   /note="Q->A: Reduces binding to MYCN."
FT                   /evidence="ECO:0000269|PubMed:27837025"
FT   MUTAGEN         346
FT                   /note="F->A: Decreases the interaction with phosphatase
FT                   type 1 isoforms."
FT                   /evidence="ECO:0000269|PubMed:11551964"
FT   MUTAGEN         393
FT                   /note="C->A: Enhances stability; when associated with
FT                   A-290."
FT                   /evidence="ECO:0000269|PubMed:27837025"
FT   HELIX           130..132
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   STRAND          133..141
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   STRAND          143..152
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   TURN            153..156
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   STRAND          157..165
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           166..172
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           175..185
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   STRAND          191..193
FT                   /evidence="ECO:0007829|PDB:3UO6"
FT   STRAND          196..201
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   STRAND          203..210
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   STRAND          214..217
FT                   /evidence="ECO:0007829|PDB:2J50"
FT   HELIX           218..225
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           230..249
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   STRAND          252..254
FT                   /evidence="ECO:0007829|PDB:6XKA"
FT   HELIX           259..261
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   STRAND          262..264
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   STRAND          266..268
FT                   /evidence="ECO:0007829|PDB:3UOL"
FT   STRAND          270..272
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           275..277
FT                   /evidence="ECO:0007829|PDB:5ORL"
FT   STRAND          280..283
FT                   /evidence="ECO:0007829|PDB:5L8L"
FT   HELIX           288..291
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           293..295
FT                   /evidence="ECO:0007829|PDB:5L8J"
FT   HELIX           298..302
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           304..306
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           307..309
FT                   /evidence="ECO:0007829|PDB:6C2T"
FT   HELIX           310..324
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           334..342
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   STRAND          350..352
FT                   /evidence="ECO:0007829|PDB:1OL6"
FT   HELIX           354..363
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           368..370
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           374..378
FT                   /evidence="ECO:0007829|PDB:6VPM"
FT   HELIX           381..386
FT                   /evidence="ECO:0007829|PDB:6VPM"
SQ   SEQUENCE   403 AA;  45823 MW;  7C2E7B438D969187 CRC64;
     MDRSKENCIS GPVKATAPVG GPKRVLVTQQ FPCQNPLPVN SGQAQRVLCP SNSSQRIPLQ
     AQKLVSSHKP VQNQKQKQLQ ATSVPHPVSR PLNNTQKSKQ PLPSAPENNP EEELASKQKN
     EESKKRQWAL EDFEIGRPLG KGKFGNVYLA REKQSKFILA LKVLFKAQLE KAGVEHQLRR
     EVEIQSHLRH PNILRLYGYF HDATRVYLIL EYAPLGTVYR ELQKLSKFDE QRTATYITEL
     ANALSYCHSK RVIHRDIKPE NLLLGSAGEL KIADFGWSVH APSSRRTTLC GTLDYLPPEM
     IEGRMHDEKV DLWSLGVLCY EFLVGKPPFE ANTYQETYKR ISRVEFTFPD FVTEGARDLI
     SRLLKHNPSQ RPMLREVLEH PWITANSSKP SNCQNKESAS KQS
//
